Blood pressure, fluid retention and the cardiovascular risk of drugs.

Suppr

超能文献

作者信息

Blankfield Robert P

出版信息

Future Cardiol. 2012 Jul;8(4):489-93. doi: 10.2217/fca.12.39.

DOI:10.2217/fca.12.39

PMID:22871187

Abstract

摘要

相似文献

Blood pressure, fluid retention and the cardiovascular risk of drugs.

Future Cardiol. 2012 Jul;8(4):489-93. doi: 10.2217/fca.12.39.

Cardiovascular effects of low-dose aspirin, traditional non-steroidal anti-inflammatory drugs and coxibs.

Bull Mem Acad R Med Belg. 2010;165(1-2):115-23; discussion 124.

What price pain relief?

Circulation. 2006 Jun 27;113(25):2868-70. doi: 10.1161/CIRCULATIONAHA.106.634386. Epub 2006 Jun 19.

Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?

Ther Adv Cardiovasc Dis. 2008 Feb;2(1):53-66. doi: 10.1177/1753944707088184.

Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.

Cardiol Clin. 2008 Nov;26(4):589-601. doi: 10.1016/j.ccl.2008.06.004.

COX-2 inhibitors and cardiovascular risk.

J Cardiovasc Pharmacol. 2007 Nov;50(5):470-9. doi: 10.1097/FJC.0b013e318157f72d.

Withdrawal of rofecoxib - a wake up call for drug safety.

Kathmandu Univ Med J (KUMJ). 2004 Oct-Dec;2(4):360.

Don't blame it all on the bogey.

BMJ. 2007 Jun 16;334(7606):1250-1. doi: 10.1136/bmj.39244.680880.59.

Cardiovascular effects of cyclooxygenase-2 inhibitors.

Curr Opin Gastroenterol. 2007 Nov;23(6):617-24. doi: 10.1097/MOG.0b013e3282f026a7.

Cardiovascular risk assessment in the development of new drugs for obesity.

JAMA. 2012 Sep 19;308(11):1099-100. doi: 10.1001/jama.2012.9931.

引用本文的文献

Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study in England.

Drug Saf. 2016 Nov;39(11):1093-1104. doi: 10.1007/s40264-016-0451-8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Blood pressure, fluid retention and the cardiovascular risk of drugs.

Future Cardiol. 2012 Jul;8(4):489-93. doi: 10.2217/fca.12.39.

Cardiovascular effects of low-dose aspirin, traditional non-steroidal anti-inflammatory drugs and coxibs.

Bull Mem Acad R Med Belg. 2010;165(1-2):115-23; discussion 124.

What price pain relief?

Circulation. 2006 Jun 27;113(25):2868-70. doi: 10.1161/CIRCULATIONAHA.106.634386. Epub 2006 Jun 19.

Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?

Ther Adv Cardiovasc Dis. 2008 Feb;2(1):53-66. doi: 10.1177/1753944707088184.

Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.

Cardiol Clin. 2008 Nov;26(4):589-601. doi: 10.1016/j.ccl.2008.06.004.

COX-2 inhibitors and cardiovascular risk.

J Cardiovasc Pharmacol. 2007 Nov;50(5):470-9. doi: 10.1097/FJC.0b013e318157f72d.

Withdrawal of rofecoxib - a wake up call for drug safety.

Kathmandu Univ Med J (KUMJ). 2004 Oct-Dec;2(4):360.

Don't blame it all on the bogey.

BMJ. 2007 Jun 16;334(7606):1250-1. doi: 10.1136/bmj.39244.680880.59.

Cardiovascular effects of cyclooxygenase-2 inhibitors.

Curr Opin Gastroenterol. 2007 Nov;23(6):617-24. doi: 10.1097/MOG.0b013e3282f026a7.

Cardiovascular risk assessment in the development of new drugs for obesity.

JAMA. 2012 Sep 19;308(11):1099-100. doi: 10.1001/jama.2012.9931.

引用本文的文献

Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study in England.

Drug Saf. 2016 Nov;39(11):1093-1104. doi: 10.1007/s40264-016-0451-8.